Lineage Cell Therapeutics, Inc. - Common shares (LCTX) Institutional Ownership

13F Institutional Holders and Ownership History from Q2 2019 to Q4 2025

Type / Class
Equity / Common shares
Symbol
LCTX on NYSE
Shares outstanding
250,425,788
Price per share
$1.57
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
101,657,105
Total reported value
$169,765,783
% of total 13F portfolios
0%
Share change
+13,586,190
Value change
+$22,647,526
Number of holders
120
Price from insider filings
$1.57
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Lineage Cell Therapeutics, Inc. - Common shares (LCTX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BROADWOOD PARTNERS, L.P. 23% -5.6% $97,763,723 57,848,357 0% NEAL C. BRADSHER 12 Nov 2025
Chernett Jorey 5% $13,848,454 11,445,003 Chernett Jorey 22 Sep 2025
BlackRock, Inc. 1% -80% $2,027,626 -$8,365,103 2,234,545 -80% BlackRock, Inc. 30 Jun 2025

As of 31 Dec 2025, 120 institutional investors reported holding 101,657,105 shares of Lineage Cell Therapeutics, Inc. - Common shares (LCTX). This represents 41% of the company’s total 250,425,788 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Lineage Cell Therapeutics, Inc. - Common shares (LCTX) together control 39% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BROADWOOD CAPITAL INC 20% 49,560,992 0% 5% $82,766,857
VANGUARD GROUP INC 3.9% 9,644,276 +7.1% 0% $16,105,941
Defender Capital, LLC. 2.7% 6,829,099 3.7% $11,405,031
RAFFLES ASSOCIATES LP 2.1% 5,362,788 -0.46% 6.7% $8,955,856
COMERICA BANK 1.8% 4,600,000 0% 0.03% $7,682,000
BlackRock, Inc. 1.5% 3,834,113 +72% 0% $6,402,969
GEODE CAPITAL MANAGEMENT, LLC 0.98% 2,461,193 +1.7% 0% $4,112,193
RENAISSANCE TECHNOLOGIES LLC 0.96% 2,404,800 +26% 0.01% $4,016,016
MILLENNIUM MANAGEMENT LLC 0.84% 2,110,419 -21% 0% $3,524,400
MORGAN STANLEY 0.8% 1,998,663 +99% 0% $3,337,767
GOLDMAN SACHS GROUP INC 0.57% 1,438,746 +894% 0% $2,402,706
MARSHALL WACE, LLP 0.54% 1,362,061 0% $2,274,642
STATE STREET CORP 0.41% 1,016,211 +6.3% 0% $1,697,072
JANE STREET GROUP, LLC 0.4% 1,004,794 +594% 0% $1,678,007
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.28% 706,415 +282% 0% $1,179,713
RED CRANE WEALTH MANAGEMENT, LLC 0.24% 597,263 +17% 0.82% $997,429
CITADEL ADVISORS LLC 0.2% 507,052 +161% 0% $846,777
NORTHERN TRUST CORP 0.19% 479,273 +8.1% 0% $800,386
Informed Momentum Co LLC 0.18% 442,221 0% 0.08% $738,509
BARCLAYS PLC 0.14% 348,510 +34850900% 0% $582,012
GSA CAPITAL PARTNERS LLP 0.13% 330,981 -51% 0.05% $553,000
OMERS ADMINISTRATION Corp 0.11% 283,200 0% $472,944
SEI INVESTMENTS CO 0.11% 269,311 0% $449,749
TWO SIGMA INVESTMENTS, LP 0.11% 265,585 -25% 0% $443,527
BRIDGEWAY CAPITAL MANAGEMENT, LLC 0.09% 221,000 0% 0.01% $369,070

Institutional Holders of Lineage Cell Therapeutics, Inc. - Common shares (LCTX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 101,657,105 $169,765,783 +$22,647,526 $1.67 120
2025 Q3 87,923,479 $148,572,802 -$9,351,743 $1.69 111
2025 Q2 97,785,816 $88,366,897 -$8,826,258 $0.91 128
2025 Q1 109,349,495 $49,687,946 +$369,638 $0.45 126
2024 Q4 107,111,044 $53,827,848 +$3,921,589 $0.50 119
2024 Q3 94,568,251 $85,611,699 -$260,148 $0.91 112
2024 Q2 94,431,242 $94,175,668 +$447,460 $1.00 110
2024 Q1 93,427,423 $138,270,047 +$26,536,201 $1.48 113
2023 Q4 75,708,353 $82,523,932 +$188,614 $1.09 114
2023 Q3 75,504,077 $89,104,877 -$402,119 $1.18 102
2023 Q2 75,637,865 $106,648,039 +$8,457,693 $1.41 105
2023 Q1 69,793,059 $104,687,354 +$7,197,215 $1.50 114
2022 Q4 65,070,787 $76,138,155 +$591,571 $1.17 99
2022 Q3 64,712,443 $73,129,667 -$348,315 $1.13 88
2022 Q2 64,980,785 $102,682,821 -$12,116,491 $1.58 84
2022 Q1 72,831,378 $112,314,619 -$3,915,128 $1.54 99
2021 Q4 73,975,180 $181,237,026 -$5,349,258 $2.45 110
2021 Q3 75,827,690 $191,741,083 +$6,640,880 $2.52 106
2021 Q2 73,147,470 $208,518,897 +$38,013,987 $2.85 103
2021 Q1 60,314,515 $141,778,049 +$12,436,479 $2.35 90
2020 Q4 55,072,841 $96,924,151 +$3,142,777 $1.76 78
2020 Q3 53,561,495 $50,165,088 -$1,850,541 $0.94 65
2020 Q2 55,701,303 $48,461,276 -$6,974,131 $0.87 80
2020 Q1 63,835,650 $52,851,654 +$405,531 $0.83 81
2019 Q4 63,343,880 $56,369,746 -$1,146,000 $0.89 86
2019 Q3 64,455,811 $63,153,426 +$63,033,394 $0.98 81
2019 Q2 17,974 $20,000 +$20,000 $1.11 1